Abbott down 2% premarket after trimming EPS range

Abbott Laboratories (ABT) Q3 results: Revenues: $8,076M (+5.5%); Nutrition: $1,874M (+2.0%); Diagnostics: $1,909M (+4.7%); Established Pharmaceuticals: $1,212M (+4.4%); Medical Devices: $3,065M (+8.9%).

Net Income: $960M (+73.9%); EPS: $0.53 (+71.0%); Non-GAAP Net Income: $1,514M (+12.8%); Non-GAAP EPS: $0.84 (+12.0%).

2019 Guidance: GAAP EPS: $2.06 – 2.08 from $2.06 – 2.12; Non-GAAP EPS: $3.23 – 3.25 from $3.21 – 3.27.

Q4 Guidance: GAAP EPS: $0.59 – 0.61; Non-GAAP EPS: $0.94 – 0.96.

Shares are down 2% premarket.

https://seekingalpha.com/news/3506062-abbott-2-percent-premarket-trimming-eps-range